HENGRUI PHARMA (01276.HK) 0.000 (0.000%) Short selling $46.38M; Ratio 20.840% announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals, has received the Drug Clinical Trial Approval Notice for the SHR-3079 injection issued by the National Medical Products Administration, and will commence clinical trials in the near term. SHR-3079 injection is an innovative anti-tumor drug independently developed by the company, and is intended for the treatment of B-cell non-Hodgkin lymphoma. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-19 16:25.)Related News Citi Cuts HSI 2026 TP to 29,600; TENCENT (00700.HK), AIA (01299.HK) Among Top H Shrs Picks
AASTOCKS Financial News